CAM
SGMT icon

Cresset Asset Management’s Sagimet Biosciences SGMT Stock Holding History

Cresset Asset Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Hold
20,079
– – ﹤0.01% 1539
2025
Q4 		$119K Buy
+20,079
New +$144K ﹤0.01% 1565

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cresset Asset Management's SGMT Position: Q1 2026 in Review

Cresset Asset Management held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 20,079 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Cresset Asset Management first reported a position in SGMT in Q4 2025 and has held it in 2 quarters since. The position peaked at $119K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Cresset Asset Management held 20,079 shares of Sagimet Biosciences worth $105K as of Q1 2026.
  • Cresset Asset Management left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1539 holding.
  • Cresset Asset Management first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Cresset Asset Management's Sagimet Biosciences position peaked at $119K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.